Amgen (AMGN) closed at $432.49 on Oct 16, 2026, down 0.4% on the day. The stock is up 13.9% over the past month, up 18.8% over three months, up 33.1% year to date and up 47.5% over the past year. It trades 3.3% below its 52-week high of $447.03 and 52.3% above its 52-week low of $283.99. The close sits above its 50-day moving average ($415.01) and above its 200-day moving average ($368.53).
NextPick tracks AMGN in its Pharma basket alongside JNJ, ABBV, MRK, RHHBY and NVS. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month AMGN ranks 1st of 12 basket members by price change.
AMGN is scheduled to report earnings on Nov 3, 2026, after market close.
Form 4 filings over the last 90 days show no open-market purchases and 6 open-market sales by insiders.
Amgen is scheduled to report on Nov 3, 2026, after market close.
Yes — the Oct 16, 2026 close of $432.49 is 17.4% above the 200-day average of $368.53.
AMGN closed 3.3% below its 52-week high of $447.03.
NextPick groups AMGN with JNJ, ABBV, MRK, RHHBY and NVS in its Pharma basket.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development
